Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Teva Pharmaceutical Industries : FDA approves a generic version of Teva Pharmaceutical's best-selling drug; company shares tumble

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/04/2017 | 07:26pm CEST

Oct. 04--Teva Pharmaceutical Industries, grappling with a tough pricing environment for its generics business and planned layoffs of 7,000 employees worldwide, received a major blow Wednesday.

The Food and Drug Administration approved rival Mylan Labs' generic version of Teva's best-selling multiple sclerosis drug.

Teva is the world's largest maker of generic pharmaceuticals, but its branded medicine Copaxone is the company's best seller with global sales of $1.02 billion in the second quarter.

Mylan shares soared nearly 20 percent while Teva's stock fell more than 14 percent Wednesday morning.

"Lightning has struck," pharmaceutical analyst Ken Cacciatore of Cowen & Co. wrote in a client note. "Mylan has achieved what it had been unable to do over the last seven years, which was garner an approval for Copaxone."

Mylan said in a statement that shipping was imminent for its generic Glatiramer Acetate 40-milligram three times a week injection and its 20-milligram once injection.

Multiple sclerosis is a chronic disease of the central nervous system and affects an estimated 400,000 Americans.

The approvals "mark another significant milestone for our company," said Mylan CEO Heather Bresch in a news release, "and reinforces our proven capabilities in bringing complex and difficult to manufacture products to market."

Teva responded that "any launch by Mylan of a generic version of Copaxone 40-milligram prior to final resolution of the pending patent appeals and other patent litigation should be considered an 'at-risk' launch, which could subject Mylan to significant damages among other remedies."

Teva's interim president and CEO Yitzhak Peterburg said Teva has planned for the eventual introduction of a generic competitor.

"We remain confident in patient and physician loyalty to Teva's Copaxone due to its recognized efficacy, safety, and tolerability profile," he said, "and we will continue to promote and support the product." Teva said it was "too soon to officially comment on any change to our full-year business outlook."

Israel-based Teva's North America headquarters are in North Wales, Montgomery County. Teva employs more than 2,000 at five locations in Pennsylvania.

Mylan Labs is based in Canonsburg, Pa. The FDA said on Monday that it planned to introduce new measures to speed up bringing generic versions of complex drugs to market, as the government agency tries to deal with the rising cost of prescription medicines in the United States.

In a statement, Teva said it has two appeals that will be argued before a panel of judges on the U.S. Court of Appeals for the Federal Circuit. Teva said its early assessment of generic glatiramer acetate product launches is that its shares could be impacted "by at least 25 cents a share in the fourth quarter ending Dec. 31." Teva said it will provide additional details on its third-quarter earnings conference call on Nov. 2.

In a client note, Cacciatore said, "the approval of Mylan's 20 and 40- milligram Copaxone is the long-feared scenario that has now come true." At the same time, another drug maker Momenta/Sandoz is seeking approval of its 40 milligram generic version of Copaxone. "It will also eventually come, whether later next year or in early 2019," the analyst wrote.

Teva last month named a permanent CEO, Kare Schultz of Denmark's Lundbeck A/S, who was hired to engineer a turnaround as Teva grapples with a tough generic pricing environment.

Teva earlier announced a restructuring after Teva spent $40.5 billion in 2015 to buy out Allergan's generic business that has proven to be a drag on earnings.

___

(c)2017 Philly.com

Visit Philly.com at www.philly.com

Distributed by Tribune Content Agency, LLC.

© Tribune Content Agency, source Regional News

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
07/17PAXMAN PUBL : receives first order from Teva in Mexico for 17 scalp cooling syst..
AQ
07/17TEVA PHARMACEUTICAL INDUSTRIES : Highlights Key Milestones Achieved in the 2017 ..
BU
07/16TEVA PHARMACEUTICAL INDUSTRIES : Previous ArticleTeva Reports First Quarter 2018..
AQ
07/13TEVA PHARMACEUTICAL INDUSTRIES : FDA Recalls Several Medicines That Contain Vals..
DJ
07/13TEVA PHARMACEUTICAL INDUSTRIES : to Report Second Quarter 2018 Financial Results..
AQ
07/12TEVA PHARMACEUTICAL INDUSTRIES : Researchers at Teva Pharmaceutical Report New D..
AQ
07/12TEVA PHARMACEUTICAL INDUSTRIES : Mylan generic Copaxone price cut puzzles indust..
AQ
07/11TEVA PHARMACEUTICAL INDUSTRIES : Announces Launch of a Generic Version of Uceris..
AQ
07/11TEVA PHARMACEUTICAL INDUSTRIES : to Report Second Quarter 2018 Financial Results..
BU
07/09Trump slams Pfizer after July 1 drug price hikes
RE
More news
News from SeekingAlpha
07/11YOUR DAILY PHARMA SCOOP : IsoRay Doubles, OncoCyte Zooms, Celgene Sluggish 
07/11Big Pharma in the red after Pfizer backs away from price hikes 
07/10Pricing transparency law in California having effect, drug makers nix planned.. 
07/10Crinetics Pharmaceuticals Readies $80 Million IPO 
07/09Biotechs give up gains after Trump tweet on prices 
Financials ($)
Sales 2018 19 600 M
EBIT 2018 -
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 1,21x
Capi. / Sales 2019 1,21x
Capitalization 23 665 M
Chart TEVA PHARMACEUTICAL INDUST
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Technical analysis trends TEVA PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 19,5 $
Spread / Average Target -16%
Managers
NameTitle
Kåre Schultz President, Chief Executive Officer & Director
Sol J. Barer Chairman
Carlo de Notaristefani Executive Vice President-Global Operations
Michael McClellan Chief Financial Officer & Executive Vice President
Amir Elstein Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED30.09%23 665
JOHNSON & JOHNSON-8.53%346 292
PFIZER3.98%220 236
ROCHE HOLDING LTD.-5.88%200 995
NOVARTIS-5.10%200 139
MERCK AND COMPANY11.85%168 225